Residential Substance Use Disorder Treatment Act of 2023

HR 238, the Residential Substance Use Disorder Treatment Act of 2023, updates federal funding programs to support residential treatment for substance use disorders in correctional facilities. It expands eligibility to include all FDA-approved medications (not just opioids) for medication-assisted treatment (MAT), requires staff training on addiction science and MAT options, and mandates partnerships with post-release providers to continue care. The bill directs $40 million annually (2023-2027) for state and local correctional facilities, including a 10% allocation for jail-based programs serving people awaiting trial or in pre-trial detention. Key changes include replacing outdated "substance abuse" terminology with "substance use disorder" throughout the law and adding requirements for evidence-based MAT coverage and continuity of care planning.